In addition, treatment with vorinostat and givinostat ex vivo and in vivo blocks deacetylation of non-histone protein STAT3, which attenuates GvHD by enhancing indoleamine 2,3-dioxygenase (IDO) expression in BMDCs and recipient APCs. The gene discussed is IDO1; the disease is graft versus host disease.